Fjarde Ap-fonden’s Teva Pharmaceuticals TEVA Stock Holding History

Fjarde Ap-fonden’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17M	Buy	502,563 +43,120	+9%	+$1.44M	0.08%	225
2026 Q1	$13.8M	Buy	459,443 +140,700	+44%	+$4.53M	0.08%	229
2025 Q4	$9.95M	Buy	+318,743	New	+$7.85M	0.08%	221
2025 Q3	–	Sell	-346,104	Closed	-$5.8M	–	491
2025 Q2	$5.8M	Buy	346,104 +54,300	+19%	+$876K	0.05%	304
2025 Q1	$4.49M	Sell	291,804 -19,339	-6%	-$345K	0.05%	322
2024 Q4	$6.86M	Buy	311,143 +7,193	+2%	+$131K	0.07%	265
2024 Q3	$5.48M	Buy	+303,950	New	+$5.32M	0.06%	325
2024 Q1	$5.2M	Buy	368,323 +6,268	+2%	+$79K	0.06%	335
2023 Q4	$3.78M	Buy	362,055 +10,885	+3%	+$102K	0.05%	397
2023 Q3	$3.58M	Buy	351,170 +18,519	+6%	+$172K	0.05%	393
2023 Q2	$2.5M	Buy	332,651 +174,700	+111%	+$1.42M	0.03%	461
2023 Q1	$1.4M	Sell	157,951 -32,549	-17%	-$322K	0.02%	487
2022 Q4	$1.74M	Sell	190,500 -159,500	-46%	-$1.39M	0.02%	474
2022 Q3	$2.63M	Hold	350,000	–	–	0.03%	468
2022 Q2	$2.63M	Hold	350,000	–	–	0.03%	468
2022 Q1	$3.29M	Hold	350,000	–	–	0.03%	471
2021 Q4	$2.8M	Buy	350,000 +150,000	+75%	+$1.35M	0.02%	510
2021 Q3	$1.95M	Hold	200,000	–	–	0.02%	539
2021 Q2	$1.98M	Hold	200,000	–	–	0.02%	550
2021 Q1	$2.31M	Hold	200,000	–	–	0.02%	540
2020 Q4	$1.93M	Hold	200,000	–	–	0.02%	549
2020 Q3	$1.8M	Hold	200,000	–	–	0.02%	562
2020 Q2	$2.47M	Hold	200,000	–	–	0.03%	491
2020 Q1	$1.8M	Hold	200,000	–	–	0.03%	499
2019 Q4	$1.96M	Hold	200,000	–	–	0.02%	565
2019 Q3	$1.38M	Hold	200,000	–	–	0.02%	569
2019 Q2	$1.85M	Hold	200,000	–	–	0.02%	549
2019 Q1	$3.14M	Hold	200,000	–	–	0.04%	450
2018 Q4	$3.08M	Hold	200,000	–	–	0.05%	363
2018 Q3	$4.31M	Hold	200,000	–	–	0.06%	347
2018 Q2	$4.86M	Buy	+200,000	New	+$4.08M	0.07%	291

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Fjarde Ap-fonden's TEVA Position: Q2 2026 in Review

Fjarde Ap-fonden increased its Teva Pharmaceuticals (TEVA) stake by 9.4% in Q2 2026, buying an estimated $1.44M and bringing the position to 502,563 shares worth $17M. The position accounts for 0.08% of the portfolio, ranked #225.

Fjarde Ap-fonden first reported a position in TEVA in Q2 2018 and has held it in 31 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Fjarde Ap-fonden held 502,563 shares of Teva Pharmaceuticals worth $17M as of Q2 2026.
Fjarde Ap-fonden bought 43,120 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
Teva Pharmaceuticals made up 0.08% of Fjarde Ap-fonden's portfolio in Q2 2026, its #225 holding.
Fjarde Ap-fonden first reported a position in Teva Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.